4.7 Article

Patient Management After Noninvasive Cardiac Imaging Results From SPARC (Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in Coronary Artery Disease)

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 59, Issue 5, Pages 462-474

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2011.09.066

Keywords

cardiac; imaging; noninvasive

Funding

  1. NHLBI [HL101060-01]
  2. Bracco Diagnostics Inc.
  3. Astellas Pharma US, Inc.
  4. GE Healthcare
  5. Siemens Medical Solutions
  6. Astellas
  7. Siemens
  8. Bracco
  9. Astellas Pharma US Inc.
  10. LMI
  11. GE
  12. Nordion
  13. GE Healthcare, Pfizer
  14. AstraZeneca
  15. Astellas Pharma Inc.
  16. Abbott Vascular
  17. Volcano
  18. Abbott Pharma
  19. Toshiba America Medical Systems
  20. Vital Images
  21. CardioDx
  22. Merck
  23. Cardiogenesis
  24. BD Medical
  25. Bracco Diagnostics
  26. Lantheus
  27. Bayer
  28. Medrad
  29. GE Health
  30. Gilead
  31. Forest Laboratories
  32. GE Medical
  33. Toshiba Medical Imaging

Ask authors/readers for more resources

Objectives This study examined short-term cardiac catheterization rates and medication changes after cardiac imaging. Background Noninvasive cardiac imaging is widely used in coronary artery disease, but its effects on subsequent patient management are unclear. Methods We assessed the 90-day post-test rates of catheterization and medication changes in a prospective registry of 1,703 patients without a documented history of coronary artery disease and an intermediate to high likelihood of coronary artery disease undergoing cardiac single-photon emission computed tomography, positron emission tomography, or 64-slice coronary computed tomography angiography. Results Baseline medication use was relatively infrequent. At 90 days, 9.6% of patients underwent catheterization. The rates of catheterization and medication changes increased in proportion to test abnormality findings. Among patients with the most severe test result findings, 38% to 61% were not referred to catheterization, 20% to 30% were not receiving aspirin, 35% to 44% were not receiving a beta-blocker, and 20% to 25% were not receiving a lipid-lowering agent at 90 days after the index test. Risk-adjusted analyses revealed that compared with stress single-photon emission computed tomography or positron emission tomography, changes in aspirin and lipid-lowering agent use was greater after computed tomography angiography, as was the 90-day catheterization referral rate in the setting of normal/nonobstructive and mildly abnormal test results. Conclusions Overall, noninvasive testing had only a modest impact on clinical management of patients referred for clinical testing. Although post-imaging use of cardiac catheterization and medical therapy increased in proportion to the degree of abnormality findings, the frequency of catheterization and medication change suggests possible undertreatment of higher risk patients. Patients were more likely to undergo cardiac catheterization after computed tomography angiography than after single-photon emission computed tomography or positron emission tomography after normal/nonobstructive and mildly abnormal study findings. (Study of Perfusion and Anatomy's Role in Coronary Artery [CAD] [SPARC]; NCT00321399) (J Am Coll Cardiol 2012; 59: 462-74) (C) 2012 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available